|
|
|
|
Work With Tiny Worm Could Point To New Treatments For Human Brain Disorders
Although the tiny roundworm Caenorhabditis elegans has only 302 neurons in its entire nervous system, studies of this simple animal have significantly advanced our understanding of human brain function because it shares many genes and...
|
|
|
Researchers Find New Actions of Neurochemicals
Dopamine and serotonin are members of a class of neurochemicals called biogenic amines, which function in neuronal circuitry throughout the brain.Many drugs used to treat psychiatric disorders, including depression and schizophrenia...
|
|
|
Researchers Find New Actions of Neurochemicals
ELEGANS, WORM, CHLORIDE CHANNELS, DOPAMINE, BIOGENIC AMINES, DEPRESSION, SCHIZOPHRENIA Contact Information Available for logged-in reporters only Description Although the tiny roundworm Caenorhabditis elegans has only 302 neurons in its...
|
|
|
MIT researchers find new actions of neurochemicals
Work with tiny worm could point to new treatments for human brain disorders VIDEO:This is C.elegans responding to a touch stimulus. Although the tiny roundworm Caenorhabditis elegans has only 302 neurons in its entire nervous system,...
|
|
|
Sepracor Provides Update on Clinical Trials for SEP-225289 and LUNESTA Pediatrics
Sepracor Inc.(Nasdaq: SEPR) today announced that it has completed the analysis and validation of the preliminary results of a Phase II, 514-patient study evaluating the efficacy and safety of SEP-225289 for the treatment of Major...
|
|
|
Duloxetine, SSRIs Produce Similar Rates of Sexual Dysfunction in Patients With Depression: Presented at WCBP
my personal edition> depression > news E-Mail this DGDispatch to a colleague DGDispatch PARIS -- July 2, 2009 -- The frequency of treatment-emergent sexual dysfunction (TESD) in patients with major depressive disorder (MDD) is...
|
|
|
Researchers Find New Actions Of Neurochemicals
Work with tiny worm could point to new treatments for human brain disorders Although the tiny roundworm Caenorhabditis elegans has only 302 neurons in its entire nervous system, studies of this simple animal have significantly advanced our...
|
|
|
New Actions Of Neurochemicals Discovered
Although the tiny roundworm Caenorhabditis elegans has only 302 neurons in its entire nervous system, studies of this simple animal have significantly advanced our understanding of human brain function because it shares many genes and...
|
|
|
Two Sepracor drugs suffer setback, shares tumble
SEPRACOR (UPDATE 1):UPDATE 1- * Sepracor depression drug ineffective in mid-stage study * FDA puts hold on pediatric studies of Lunesta NEW YORK (Reuters) - U.S.biotechnology company Sepracor Inc ( SEPR - news - people ) on Wednesday...
|
|
|
UPDATE 1-Two Sepracor drugs suffer setback, shares tumble
NEW YORK, July 1 (Reuters) - U.S.biotechnology company Sepracor Inc ( SEPR - news - people ) on Wednesday suffered a double setback as its experimental depression drug failed a mid-stage study and U.S. regulators halted two pediatric...
|
|
|
Two Sepracor drugs suffer setback, shares tumble
By Ransdell Pierson NEW YORK (Reuters) - U.S.biotechnology company Sepracor Inc (SEPR.O) on Wednesday suffered a double setback as its experimental depression drug failed a mid-stage study and U.S. regulators halted two pediatric...
|
|
|
Interaction Between the Serotonin Transporter Gene (5-HTTLPR), Stressful Life Events, and Risk of Depression
Neil Risch, PhD; Richard Herrell, PhD; Thomas Lehner, PhD; Kung-Yee Liang, PhD; Lindon Eaves, PhD; Josephine Hoh, PhD; Andrea Griem, BS; Maria Kovacs, PhD; Jurg Ott, PhD; Kathleen Ries Merikangas, PhD Context Substantial resources are being...
|
|
|
Milnacipran: A serotonin and norepinephrine reuptake inhibitor for the management of fibromyalgia syndrome
Milnacipran is a serotonin and norepinephrine reuptake inhibitor (SNRI) that was recently approved by FDA for the management of fibromyalgia syndrome (FMS).In clinical trials, milnacipran has demonstrated efficacy in reducing FMS...
|
|
|
MIT researchers find new actions of neurochemicals
Although the tiny roundworm Caenorhabditis elegans has only 302 neurons in its entire nervous system, studies of this simple animal have significantly advanced our understanding of human brain function because it shares many genes and...
|
|
|
Duloxetine, SSRIs Produce Similar Rates of Sexual Dysfunction in Patients With Depression: Presented at WCBP
-- The frequency of treatment-emergent sexual dysfunction (TESD) in patients with major depressive disorder (MDD) is about the same whether patients are treated with duloxetine hydrochloride or a selective serotonin reuptake inhibitor ...
|
|
|
Sepracor Provides Update On Clinical Trials For SEP-225289 And LUNESTA(R) Pediatrics
Sepracor Inc.(Nasdaq: SEPR) announced that it has completed the analysis and validation of the preliminary results of a Phase II, 514-patient study evaluating the efficacy and safety of SEP-225289 for the treatment of Major Depressive...
|
|
|
Sepracor depression drug flunks a mid-stage test
Sepracor ran into an unexpected setback on a mid-stage therapeutic for depression.Researchers say that the drug--SEP-225289--failed to deliver positive data in a trial that dosed 514 patients over eight weeks. The developer says that...
|
|
|
Sepracor tumbles as drugs suffer setback
NEW YORK - Sepracor Inc., a Marlborough, Mass., biotechnology company, yesterday suffered a double setback as its experimental depression drug failed a midstage study and US regulators halted two pediatric studies of its blockbuster Lunesta...
|
|
|
Sepracor Provides Update on Clinical Trials for SEP-225289 and LUNESTA Pediatrics
MARLBOROUGH, Mass.Sepracor Inc. (Nasdaq: SEPR) today announced that it has completed the analysis and validation of the preliminary results of a Phase II, 514-patient study evaluating the efficacy and safety of SEP-225289 for the...
|
|
|
Sepracor Provides Update on Clinical Trials for SEP-225289 and LUNESTA Pediatrics
- Sepracor Inc.(Nasdaq: SEPR) today announced that it has completed the analysis and validation of the preliminary results of a Phase II, 514-patient study evaluating the efficacy and safety of SEP-225289 for the treatment of Major...
|
|
|
Sepracor Clinical Depressive Disorder Drug Misses Primary Endpoint In Phase II Trials - Quick Facts
PM ET RELATED NEWS TOP MARKET NEWS (RTTNews) - Wednesday, Sepracor Inc.(SEPR: News ) said its Phase II clinical trail to evaluate efficacy and safety of SEP-225289 for treatment of major depressive disorder did not meet the primary end...
|
|
|
Sepracor Provides Update on Clinical Trials for SEP-225289 and LUNESTA Pediatrics
Sepracor Inc.(Nasdaq: SEPR) today announced that it has completed the analysis and validation of the preliminary results of a Phase II, 514-patient study evaluating the efficacy and safety of SEP-225289 for the treatment of Major...
|
|
|
UPDATE 1-Two Sepracor drugs suffer setback, shares tumble
* Sepracor depression drug ineffective in mid-stage study * FDA puts hold on pediatric studies of Lunesta NEW YORK, July 1 (Reuters) - U.S.biotechnology company Sepracor Inc (SEPR.O) on Wednesday suffered a double setback as its...
|
|
|
UPDATE 1-Two Sepracor drugs suffer setback, shares tumble
NEW YORK, July 1 (Reuters) - U.S.biotechnology company Sepracor Inc on Wednesday suffered a double setback as its experimental depression drug failed a mid-stage study and U.S. regulators halted two pediatric studies of its blockbuster...
|
|
|
[PAPERS] Serotonin transporter genotype, morning cortisol and subsequent depression in adolescents
The British Journal of Psychiatry (2009) 195: 39-45.doi: 10.1192/bjp.bp.108.054775 2009 The Royal College of Psychiatrists OPEN ACCESS ARTICLE This Article This is an Open Access article Submit an eLetter Citing Articles Google Scholar ...
|
